Valuation: Ionis Pharmaceuticals, Inc.

Market Cap 9.76B 8.36B 7.8B 7.16B 13.45B 934B 13.71B 92.54B 36.07B 468B 36.67B 35.87B 1,550B P/E 2026 *
-16.1x
P/E 2027 * -31.1x
Enterprise Value 9.66B 8.27B 7.72B 7.08B 13.31B 925B 13.57B 91.57B 35.69B 463B 36.28B 35.49B 1,534B EV / Sales 2026 *
10.6x
EV / Sales 2027 * 7.01x
Free-Float
99.05%
Yield 2026 *
-
Yield 2027 * -
1 day-3.36%
1 week+5.17%
Current month+13.50%
1 month+10.97%
3 months-21.72%
6 months-29.33%
Current year-25.72%
1 week 56.41
Extreme 56.41
61.36
1 month 50
Extreme 50.005
61.36
Current year 50
Extreme 50.005
86.74
1 year 41.7
Extreme 41.705
86.74
3 years 23.95
Extreme 23.95
86.74
5 years 23.95
Extreme 23.95
86.74
10 years 23.95
Extreme 23.95
86.74
Manager TitleAgeSince
Investor Relations Contact 60 01/07/2012
Chief Executive Officer 64 01/01/2020
Director of Finance/CFO 64 01/05/2000
Director TitleAgeSince
Director/Board Member 64 13/12/2005
Director/Board Member 73 01/05/2002
Director/Board Member 64 25/03/2019
Date Insider Type Main position Quantity % Market Cap.
7/31/26 A Buy

Director

5,000 0.0030%
7/15/26 A Free

Director

3,399 0.0021%
7/15/26 A Free

Director

3,399 0.0021%
Change 5-day change 1-year change 3-year change Capi.($)
-3.36%+5.17%+37.26%+51.25% 9.76B
-0.48%+3.73%+2.93%+24.20% 51.22B
-1.36%+4.82%+485.55%+614.84% 45.38B
-2.04%+3.69%+19.34%+91.23% 41.97B
+2.72%+6.02%+33.33%+19.66% 42.15B
0.00%-3.91%+18.49%+47.98% 31.95B
-1.85%+3.48% - - 16.73B
+0.72%+5.27%+31.55%+145.37% 17.1B
-0.58%+2.78%+6.47%+34.67% 14.76B
+0.50%+3.62%+82.64%+46.53% 13.91B
Average -0.58%+3.43%+79.73%+119.52% 28.49B
Weighted average by Cap. -0.39%+3.25%+101.19%+147.19%

Financials

2026 *2027 *
Net sales 913M 782M 730M 670M 1.26B 87.4B 1.28B 8.66B 3.37B 43.8B 3.43B 3.36B 145B 1.4B 1.2B 1.12B 1.03B 1.93B 134B 1.97B 13.29B 5.18B 67.24B 5.26B 5.15B 223B
Net income -602M -516M -481M -442M -830M -57.64B -846M -5.71B -2.23B -28.89B -2.26B -2.21B -95.64B -326M -279M -260M -239M -449M -31.18B -458M -3.09B -1.2B -15.63B -1.22B -1.2B -51.73B
Net Debt -103M -88.16M -82.25M -75.48M -142M -9.85B -145M -976M -380M -4.94B -387M -378M -16.35B 57.45M 49.19M 45.9M 42.12M 79.14M 5.5B 80.69M 544M 212M 2.76B 216M 211M 9.12B
Logo Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Employees
1,480
Date Price Change Volume
20/08/26 $58.76 -3.36% 2,124,846
19/08/26 $60.80 +1.98% 3,137,560
18/08/26 $59.62 +1.69% 3,192,640
17/08/26 $58.63 +2.43% 2,000,182
14/08/26 $57.24 +2.45% 1,353,737
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
58.76USD
Average target price
88.00USD
Spread / Average Target
+49.76%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IONS Stock